Elevated Platelet Count as Prognostic Factor in Colorectal Cancer With Synchronous Liver Metastases

Colorectal cancer (CRC) is the third most common malignancy worldwide and is often metastatic at diagnosis. Despite progresses in surgical techniques and the introduction of novel chemotherapy regimens, many patients still suffer from a poor prognosis. It is therefore of utmost importance to identify prognostic markers that may improve selection of patients.

In recent years several studies demonstrated that preoperative blood tests as platelet count or neuthophil-to-lymphocyte ratio could be prognostic factors in CRC as well as other malignancies. The aim of this study was to evaluate the role of preoperative platelet count (PC) in patients with synchronous colorectal liver metastases.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Colorectal Cancer Blood Platelet Disorders Bone Marrow Diseases Colonic Diseases Colonic Neoplasms Colorectal Carcinoma Colorectal Neoplasms Digestive System Diseases Digestive System Neoplasms Gastrointestinal Diseases Gastrointestinal Neoplasms Hematologic Diseases Hemic and Lymphatic Diseases Intestinal Diseases Intestinal Neoplasms Myeloproliferative Disorders Neoplasms Neoplasms by Site Rectal Diseases Stage IV Colon Cancer Thrombocytosis

Age range

18 year–100 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Chirurgia Generale ed Epatobiliare, Policlinico GB Rossi

Verona, 37134, Italy

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Colorectal cancer with synchronous liver metastases
Possibility to retrieve pre-operative platelet count
Age of 18 years or older
Availabilty of clinical-pathological data
Minimum follow up of 12 months

Exclusion criteria

None

Treatment and study plan

Measurement of platelet count at diagnosis

Diagnostic Test

Blood samples were drawn by expert phlebotomists in vacuum blood tubes containing K2-EDTA (Terumo Europe NV, Leuven, Belgium). The complete blood cell count (CBC) was performed using Advia 2120 (Siemens Healthcare Diagnostics, Tarrytown NY, USA). The local reference range for platelets was 150-400 x 109/L. The same analyser was used throughout the study period, and the quality and reproducibility of test results was validated by data of both internal quality control and external quality assessment

Primary outcomes

Overall survival

Time frame: 5 years

correlation between high PC and overall survival

Secondary outcomes

Clinic-pathological variables

Time frame: 30 days

correlation between high PC and clinic-pathological variables

Sponsors and collaborators

Lead sponsor

Azienda Ospedaliera Universitaria Integrata Verona

Other

Registry information

Official study title

Elevated Platelet Count as Prognostic Factor in Colorectal Cancer With Synchronous Liver Metastases: a Retrospective Single-center Cohort Study

Acronym: PLTCRC

Important dates

Study start: 2018
Primary completion: 2018
Study completion: 2018
First posted: Oct 24, 2018
Registry last updated: Jul 20, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed